Nintedanib Eugia

Nintedanib, the active ingredient in Nintedanib Eugia, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain forms of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nintedanib Eugia acts on multiple receptor tyrosine kinases involved in fibrotic and oncogenic pathways, providing therapeutic benefit in several serious lung conditions.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: mitigates fibrotic changes and preserves respiratory capacity. - Non‑small cell lung cancer: used in combination regimens to inhibit tumor growth and angiogenesis.

Nintedanib may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea and vomiting: gastrointestinal discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Decreased appetite: reduced desire to eat, potentially leading to weight loss. - Elevated liver enzymes: mild increases in ALT/AST. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, marked enzyme elevation, or hepatic failure. - Major bleeding events: gastrointestinal or intracranial hemorrhage. - Cardiovascular complications: myocardial infarction or stroke. - Gastrointestinal perforation: severe abdominal pain requiring urgent care. - Severe infections: opportunistic or bacterial infections. - Pulmonary embolism: sudden shortness of breath or chest pain.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant clinical parameters.

- Liver function monitoring: check ALT/AST before treatment and periodically thereafter. - Bleeding risk assessment: avoid in patients with active bleeding or uncontrolled anticoagulation. - Cardiovascular evaluation: caution in patients with recent myocardial infarction or uncontrolled hypertension. - Pregnancy and lactation: avoid use due to unknown safety; discuss contraception. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib can interact with several drug classes, influencing its efficacy and safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Potent P‑gp inhibitors (e.g., verapamil): can raise plasma concentrations. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of serious bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for additive bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding potential.